Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019)
Alx Oncology Holdings' (ALXO) quarterly Non-Current Deffered Revenue came in at $135000.0 in Q4 2019.
Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019) Analysis & Trends
Alx Oncology Holdings has disclosed Non-Current Deffered Revenue across 1 years of filings, most recently posting $135000.0 for Q4 2019.
- Non-Current Deffered Revenue for Q4 2019 came in at $135000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $135000.0 (changed N/A YoY), and the FY2019 annual result was $135000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $135000.0 for Q4 2019 at Alx Oncology Holdings.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $135000.0 in Q4 2019 to a low of $135000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Alx Oncology Holdings | 166.27 Mn | 25.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 135,000.00 |